SK bioscience , a Korean vaccine maker, said it has begun construction of its global research and process development (R&PD) center in Songdo, Incheon

The subsidiary of Korean conglomerate SK Group, plans to complete the construction of the R&PD center by the first half of 2025.

Upon completion, the center will relocate the company´s headquarters and laboratories, currently located in Pangyo, Gyeonggi Province, to Songdo.

The relocation will cost around 325.7 billion won ($251.5 million).